» Articles » PMID: 1284562

Differential Analgesic Effects of Aspirin-like Drugs

Overview
Journal Drugs
Specialty Pharmacology
Date 1992 Jan 1
PMID 1284562
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue damage, including that due to surgical manipulation, results in 2 distinct but connected changes in the pain perception pathway. Firstly, cells disintegrate at the site of tissue damage and release mediators, including prostaglandins. These mediators transform fine nerve endings, particularly high-threshold mechanoceptors, into nociceptors. In other words, fine nerve endings that are not normally activated by mechanical pressure or temperature changes become very sensitive and are depolarised after minor mechanical or thermal changes. Secondly, in the central nervous system (CNS) and, particularly, in the dorsal horn of the spinal cord, reflex activity is increased, metabolic activity of the neuronal cells is enhanced and, chronically, major rearrangements of mediator production and electrical activity of the dorsal horn cells may be observed. Both types of change contribute to the well known phenomenon of hyperalgesia, which is regularly observed in connection with tissue damage, including that produced by surgical manipulation. It has been shown that aspirin-like drugs reduce the enhanced nociceptor activity in damaged tissue, probably as a result of prostaglandin synthesis inhibition. Recently, there have been indications that these drugs may have an additional mechanism of action in the spinal cord or higher parts of the CNS. Using the pure enantiomers of flurbiprofen in pharmacodynamic experiments in the rat, we have observed that the R- and S-enantiomers may exert differential analgesic effects. The R-enantiomer, which does not inhibit cyclo-oxygenase in vitro, was almost as effective as the S-enantiomer, which does inhibit prostaglandin synthesis in different models of pain and nociception.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors.

Voilley N, De Weille J, Mamet J, Lazdunski M J Neurosci. 2001; 21(20):8026-33.

PMID: 11588175 PMC: 6763876.


Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Wilder-Smith C Drug Saf. 1998; 18(6):457-72.

PMID: 9638390 DOI: 10.2165/00002018-199818060-00006.


Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Gillis J, Brogden R Drugs. 1997; 53(1):139-88.

PMID: 9010653 DOI: 10.2165/00003495-199753010-00012.


Preclinical and clinical development of dexketoprofen.

Mauleon D, Artigas R, Garcia M, Carganico G Drugs. 1996; 52 Suppl 5:24-45; discussion 45-6.

PMID: 8922555 DOI: 10.2165/00003495-199600525-00005.


Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat.

Pini L, Sandrini M, Vitale G Inflamm Res. 1995; 44(1):30-5.

PMID: 7664027 DOI: 10.1007/BF01630485.

References
1.
Atkinson D, COLLIER H . Salicylates: molecular mechanism of therapeutic action. Adv Pharmacol Chemother. 1980; 17:233-88. DOI: 10.1016/s1054-3589(08)60012-5. View

2.
Dembinska-Kiec A, Zmuda A, Krupinska J . Inhibition of prostaglandin synthetase by aspirin-like drugs in different microsomal preparations. Adv Prostaglandin Thromboxane Res. 1976; 1:99-103. View

3.
Ferreira S, Lorenzetti B, Correa F . Central and peripheral antialgesic action of aspirin-like drugs. Eur J Pharmacol. 1978; 53(1):39-48. DOI: 10.1016/0014-2999(78)90265-0. View

4.
Shyu K, Lin M . Hypothalamic monoaminergic mechanisms of aspirin-induced analgesia in monkeys. J Neural Transm. 1985; 62(3-4):285-93. DOI: 10.1007/BF01252242. View

5.
RAMWELL P, Shaw J . Spontaneous and evoked release of prostaglandins from cerebral cortex of anesthetized cats. Am J Physiol. 1966; 211(1):125-34. DOI: 10.1152/ajplegacy.1966.211.1.125. View